Constantine Mitsiades

List of Publications by Year in Descending Order

75 papers	9,715 citations	45 h-index	77 g-index
77 ext. papers	10,326 ext. citations	5.3 avg, IF	5.14 L-index

#	Paper	IF	Citations
75	A biphenyl inhibitor of eIF4E targeting an internal binding site enables the design of cell-permeable PROTAC-degraders. *European Journal of Medicinal Chemistry*, **2021**, 219, 113435	6.8	2
74	The power of proteasome inhibition in multiple myeloma. *Expert Review of Proteomics*, **2018**, 15, 1033-1052	4.2	25
73	Inference and Analysis of Gene Regulatory Networks in R **2016**, 289-306		0
72	Identification of Wee1 as a novel therapeutic target for mutant RAS-driven acute leukemia and other malignancies. *Leukemia*, **2015**, 29, 27-37	10.7	43
71	Upregulation of IGF1R by mutant RAS in leukemia and potentiation of RAS signaling inhibitors by small-molecule inhibition of IGF1R. *Clinical Cancer Research*, **2014**, 20, 5483-95	12.9	12
70	Pomalidomide for the treatment of relapsed and refractory multiple myeloma. *Expert Opinion on Orphan Drugs*, **2014**, 2, 1089-1108	1.1	
69	Novel Agents in Multiple Myeloma **2013**, 215-228		
68	New proteasome inhibitors in myeloma. *Current Hematologic Malignancy Reports*, **2012**, 7, 258-66	4.4	74
67	Lenalidomide for the treatment of relapsed and refractory multiple myeloma. *Cancer Management and Research*, **2012**, 4, 253-68	3.6	26
66	A novel panel of protein biomarkers for predicting response to thalidomide-based therapy in newly diagnosed multiple myeloma patients. *Proteomics*, **2011**, 11, 1391-402	4.8	26
65	A proto-oncogene BCL6 is up-regulated in the bone marrow microenvironment in multiple myeloma cells. *Blood*, **2010**, 115, 3772-5	2.2	52
64	Complications of multiple myeloma therapy, part 1: risk reduction and management of peripheral neuropathy and asthenia. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2010**, 8 Suppl 1, S4-S12	7.3	26
63	Lenalidomide in multiple myeloma: an evidence-based review of its role in therapy. *Core Evidence*, **2010**, 4, 215-45	4.9	16
62	Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy. *Journal of Clinical Oncology*, **2009**, 27, 3518-25	2.2	213
61	Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells. *Blood*, **2009**, 114, 1046-52	2.2	285
60	Functional interaction of plasmacytoid dendritic cells with multiple myeloma cells: a therapeutic target. *Cancer Cell*, **2009**, 16, 309-23	24.3	197
59	Novel Combination Therapies for the Treatment of Relapsed/Refractory Multiple Myeloma: Current Phase I/II Combinations. *Clinical Lymphoma and Myeloma*, **2009**, 9, S40-S42		

58	Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. *Blood*, **2009**, 114, 371-9	2.2	331
57	Bortezomib in the front-line treatment of multiple myeloma. *Expert Review of Anticancer Therapy*, **2008**, 8, 1053-72	3.5	73
56	Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma. *Leukemia and Lymphoma*, **2008**, 49, 502-7	1.9	174
55	Lenalidomide plus dexamethasone is efficacious in patients with relapsed or refractory multiple myeloma. *Nature Clinical Practice Oncology*, **2008**, 5, 374-5		1
54	TH17 Pathway Promotes Tumor Cell Growth and Suppresses Immune Function in Myeloma: Potential for Therapeutic Application. *Blood*, **2008**, 112, 2737-2737	2.2	
53	Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. *Nature Reviews Cancer*, **2007**, 7, 585-98	31.3	699
52	Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cells. *British Journal of Haematology*, **2007**, 138, 783-91	4.5	94
51	Targeting the beta-catenin/TCF transcriptional complex in the treatment of multiple myeloma. *Proceedings of the National Academy of Sciences of the United States of America*, **2007**, 104, 7516-21	11.5	173
50	Emerging drugs in multiple myeloma. *Expert Opinion on Emerging Drugs*, **2007**, 12, 155-63	3.7	9
49	Potentiation of antileukemic therapies by Smac mimetic, LBW242: effects on mutant FLT3-expressing cells. *Molecular Cancer Therapeutics*, **2007**, 6, 1951-61	6.1	71
48	New drugs for myeloma. *Oncologist*, **2007**, 12, 664-89	5.7	138
47	The treatment of relapsed and refractory multiple myeloma. *Hematology American Society of Hematology Education Program*, **2007**, 2007, 317-23	3.1	45
46	Targeting mitochondrial factor Smac/DIABLO as therapy for multiple myeloma (MM). *Blood*, **2007**, 109, 1220-7	2.2	140
45	Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib. *Blood*, **2007**, 109, 3177-88	2.2	314
44	The emerging role of novel therapies for the treatment of relapsed myeloma. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2007**, 5, 149-62	7.3	56
43	MLN120B, a novel IkappaB kinase beta inhibitor, blocks multiple myeloma cell growth in vitro and in vivo. *Clinical Cancer Research*, **2006**, 12, 5887-94	12.9	118
42	Lenalidomide in multiple myeloma. *Expert Review of Anticancer Therapy*, **2006**, 6, 1165-73	3.5	42
41	Bortezomib: proteasome inhibition as an effective anticancer therapy. *Annual Review of Medicine*, **2006**, 57, 33-47	17.4	289

40	Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. *Blood*, **2006**, 107, 4053-62	2.2	360
39	Beyond single-agent bortezomib: combination regimens in relapsed multiple myeloma. *Current Opinion in Oncology*, **2006**, 18, 598-608	4.2	29
38	Proteasome inhibition as a new therapeutic principle in hematological malignancies. *Current Drug Targets*, **2006**, 7, 1341-7	3	38
37	Gene expression analysis of B-lymphoma cells resistant and sensitive to bortezomib. *British Journal of Haematology*, **2006**, 134, 145-56	4.5	90
36	Bortezomib Induces Proliferation of Mesenchymal Progenitor Cells and Promotes Differentiation towards Osteoblastic Lineage.. *Blood*, **2006**, 108, 88-88	2.2	4
35	Proteasome Inhibition in the Treatment of Cancer. *Cell Cycle*, **2005**, 4, 289-295	4.7	77
34	Molecular characterization of PS-341 (bortezomib) resistance: implications for overcoming resistance using lysophosphatidic acid acyltransferase (LPAAT)-beta inhibitors. *Oncogene*, **2005**, 24, 3121-9	9.2	39
33	A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. *Cancer Cell*, **2005**, 8, 407-19	24.3	611
32	Proteasome inhibitor therapy in multiple myeloma. *Molecular Cancer Therapeutics*, **2005**, 4, 686-92	6.1	142
31	Bortezomib: proteasome inhibition as an effective anticancer therapy. *Future Oncology*, **2005**, 1, 161-71	3.6	30
30	Targeting Bcl-2 as Therapy for Multiple Myeloma.. *Blood*, **2005**, 106, 109-109	2.2	5
29	Requirement of Caspase-8 Versus Caspase-9 during Apoptosis in Multiple Myeloma Cells Induced by Bortezomib- or a Novel Proteasome Inhibitor NPI-0052.. *Blood*, **2005**, 106, 3378-3378	2.2	1
28	Proteasome inhibition in the treatment of cancer. *Cell Cycle*, **2005**, 4, 290-6	4.7	40
27	Blockade of ubiquitin-conjugating enzyme CDC34 enhances anti-myeloma activity of Bortezomib/Proteasome inhibitor PS-341. *Oncogene*, **2004**, 23, 3597-602	9.2	49
26	p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells. *Oncogene*, **2004**, 23, 8766-76	9.2	112
25	Proteasome inhibition in hematologic malignancies. *Annals of Medicine*, **2004**, 36, 304-14	1.5	53
24	Thalidomide for patients with relapsed multiple myeloma after high-dose chemotherapy and stem cell transplantation: results of an open-label multicenter phase 2 study of efficacy, toxicity, and biological activity. *Mayo Clinic Proceedings*, **2004**, 79, 875-82	6.4	106
23	Identification of genes modulated in multiple myeloma using genetically identical twin samples. *Blood*, **2004**, 103, 1799-806	2.2	120

22	Immunomodulatory drug costimulates T cells via the B7-CD28 pathway. *Blood*, **2004**, 103, 1787-90	2.2	230
21	The bortezomib/proteasome inhibitor PS-341 and triterpenoid CDDO-Im induce synergistic anti-multiple myeloma (MM) activity and overcome bortezomib resistance. *Blood*, **2004**, 103, 3158-66	2.2	106
20	Targeting mitochondria to overcome conventional and bortezomib/proteasome inhibitor PS-341 resistance in multiple myeloma (MM) cells. *Blood*, **2004**, 104, 2458-66	2.2	70
19	Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma. *Blood*, **2004**, 104, 4188-93	2.2	167
18	A Novel Orally Available Proteasome Inhibitor NPI-0052 Induces Killing in Multiple Myeloma (MM) Cells Resistant to Conventional and Bortezomib Therapies.. *Blood*, **2004**, 104, 2405-2405	2.2	2
17	Comprehensive Genome-Wide Profile of Regional Gains and Losses in Multiple Myeloma Using Array-CGH: The 1q21 Amplification and Potential Role of the BCL-9 Gene in Multiple Myeloma Pathogenesis.. *Blood*, **2004**, 104, 785-785	2.2	4
16	The Akt pathway: molecular targets for anti-cancer drug development. *Current Cancer Drug Targets*, **2004**, 4, 235-56	2.8	215
15	Atiprimod (N-N-diethl-8,8-dipropyl-2-azaspiro [4.5] decane-2-propanamine) Inhibits Myeloma in Vivo.. *Blood*, **2004**, 104, 2401-2401	2.2	
14	Increased TCF-4 Expression Correlates with Reduced Caspase-3 Induction and Confers Resistance to Bortezomib.. *Blood*, **2004**, 104, 285-285	2.2	1
13	Targeting Mitochondrial Factor Smac/DIABLO as Therapy for Multiple Myeloma (MM).. *Blood*, **2004**, 104, 764-764	2.2	
12	JNK-dependent release of mitochondrial protein, Smac, during apoptosis in multiple myeloma (MM) cells. *Journal of Biological Chemistry*, **2003**, 278, 17593-6	5.4	169
11	Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. *Blood*, **2003**, 101, 1530-4	2.2	488
10	Identification of genes regulated by 2-methoxyestradiol (2ME2) in multiple myeloma cells using oligonucleotide arrays. *Blood*, **2003**, 101, 3606-14	2.2	65
9	Hsp27 inhibits release of mitochondrial protein Smac in multiple myeloma cells and confers dexamethasone resistance. *Blood*, **2003**, 102, 3379-86	2.2	131
8	CD40 induces human multiple myeloma cell migration via phosphatidylinositol 3-kinase/AKT/NF-kappa B signaling. *Blood*, **2003**, 101, 2762-9	2.2	98
7	Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myeloma. *Oncogene*, **2003**, 22, 8386-93	9.2	151
6	Insights into the multistep transformation of MGUS to myeloma using microarray expression analysis. *Blood*, **2003**, 102, 4504-11	2.2	194
5	Insulin-like growth factor-1 induces adhesion and migration in human multiple myeloma cells via activation of beta1-integrin and phosphatidylinositol 3Ŧkinase/AKT signaling. *Cancer Research*, **2003**, 63, 5850-8	10.1	138

4	Antitumor activity of lysophosphatidic acid acyltransferase-beta inhibitors, a novel class of agents, in multiple myeloma. *Cancer Research*, **2003**, 63, 8428-36	10.1	42
3	Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. *Blood*, **2002**, 100, 3063-7	2.2	693
2	NF-kappa B as a therapeutic target in multiple myeloma. *Journal of Biological Chemistry*, **2002**, 277, 16639-47	5.4	723
1	Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration. *Blood*, **2001**, 98, 428-35	2.2	358